These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30374435)

  • 1. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
    Baran-Kooiker A; Czech M; Kooiker C
    Front Public Health; 2018; 6():287. PubMed ID: 30374435
    [No Abstract]   [Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
    Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
    Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
    Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
    Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
    Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
    BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 10. Using multi-criteria decision analysis to appraise orphan drugs: a systematic review.
    Friedmann C; Levy P; Hensel P; Hiligsmann M
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):135-146. PubMed ID: 29210308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the Emirates Multi-Criteria Decision Analysis Tool for Orphan Drugs.
    Alnaqbi KA; Elezbawy B; Fasseeh AN; Bangash AR; Elshamy A; Shendi H; Aftab MI; AlMarshoodi M; Gebran N; AlDhaheri N; Fahmy SA; Al Dallal S; Al Naeem W; Abaza S; Kaló Z
    Cureus; 2024 Feb; 16(2):e55215. PubMed ID: 38558740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.
    Blonda A; Denier Y; Huys I; Simoens S
    Front Pharmacol; 2021; 12():631527. PubMed ID: 34054519
    [No Abstract]   [Full Text] [Related]  

  • 13. Societal Preferences in Health Technology Assessments for Rare Diseases and Orphan Drugs: A Systematic Literature Review of New Analytic Approaches.
    Vásquez P; Hall L; Merlo G
    Value Health Reg Issues; 2024 Jul; 44():101026. PubMed ID: 39059264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.
    Schey C; Postma MJ; Krabbe PFM; Topachevskyi O; Volovyk A; Connolly M
    Front Public Health; 2020; 8():162. PubMed ID: 32457865
    [No Abstract]   [Full Text] [Related]  

  • 15. Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis.
    Kolasa K; Zwolinski KM; Zah V; Kaló Z; Lewandowski T
    Orphanet J Rare Dis; 2018 Apr; 13(1):67. PubMed ID: 29703227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.
    Bao Y; Gao B; Meng M; Ge B; Yang Y; Ding C; Shi B; Tian L
    BMC Health Serv Res; 2021 Aug; 21(1):807. PubMed ID: 34384428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.
    Gilabert-Perramon A; Torrent-Farnell J; Catalan A; Prat A; Fontanet M; Puig-Peiró R; Merino-Montero S; Khoury H; Goetghebeur MM; Badia X
    Int J Technol Assess Health Care; 2017 Jan; 33(1):111-120. PubMed ID: 28434413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs.
    Schey C; Krabbe PF; Postma MJ; Connolly MP
    Orphanet J Rare Dis; 2017 Jan; 12(1):10. PubMed ID: 28095876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Step Toward the Development of the First National Multi-Criteria Decision Analysis Framework to Support Healthcare Decision Making in Saudi Arabia.
    Al-Jedai A; Almudaiheem H; Alruthia Y; Althemery A; Alabdulkarim H; Ojeil R; Alrumaih A; AlGhannam S; AlMutairi A; Hasnan Z
    Value Health Reg Issues; 2024 May; 41():100-107. PubMed ID: 38306770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.